<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">37264223</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-742X</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of thrombosis and thrombolysis</Title><ISOAbbreviation>J Thromb Thrombolysis</ISOAbbreviation></Journal><ArticleTitle>Positive antiphospholipid antibodies: observation or treatment?</ArticleTitle><Pagination><StartPage>301</StartPage><EndPage>314</EndPage><MedlinePgn>301-314</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11239-023-02834-6</ELocationID><Abstract><AbstractText>Antiphospholipid antibodies (APLAs) are&#xa0; primarily directed toward phospholipid-binding proteins and are responsible for thrombotic events. APLAs include anti-&#x3b2;2Glycoprotein I (anti-&#x3b2;2GPI), anticardiolipin (anti-CL) antibodies, and lupus anticoagulant. These antibodies are typical markers of antiphospholipid syndrome (APS) and are a part of its diagnostic criteria. Many data underline the presence of APLAs in other rheumatic diseases (e.g., systemic lupus erythematosus, systemic sclerosis, Sj&#xf6;gren's syndrome, rheumatoid arthritis and Beh&#xe7;et's disease). However, they are also detected in patients with cancer, infection, and neurological disorders. Furthermore, healthy individuals may be carriers of APLAs. Chronic asymptomatic APLAs presence is most common in the elderly and subjects with chronic diseases (including malignancies). Specific kinds of APLAs are considered markers of oncological progression. These antibodies occur in 6% of pregnant women (without diagnosed APS) and are related to many pregnancy complications. Of worth, various types of APLAs are reported to have different prothrombotic properties. The risk of thrombotic events in APLA-positive but clinically na&#xef;ve patients raises many questions in clinical practice. This manuscript analyses various clinical situations and consequences of the APLAs' presence, particularly in patients without diagnosed APS. The prevalence, etiology, molecular background, and prothrombotic properties of numerous APLAs are broadly discussed. The new management approach in different clinical conditions and organ complications is present in the context of recent recommendations. Discussed data underlines that adequate and timely introduced thromboprophylaxis can decrease the risk of thrombus formation and prevent increased morbidity.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grygiel-G&#xf3;rniak</LastName><ForeName>Bogna</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-3438-0764</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Rehabilitation and Internal Diseases, Poznan University of Medical Sciences, Fredry 10, 61-701, Poznan, Poland. bgrygiel@ump.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazurkiewicz</LastName><ForeName>&#x141;ukasz</ForeName><Initials>&#x141;</Initials><Identifier Source="ORCID">0000-0001-8104-8679</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Rehabilitation and Internal Diseases, Poznan University of Medical Sciences, Fredry 10, 61-701, Poznan, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Thromb Thrombolysis</MedlineTA><NlmUniqueID>9502018</NlmUniqueID><ISSNLinking>0929-5305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APLAs in a healthy population</Keyword><Keyword MajorTopicYN="N">Antiphospholipid antibodies</Keyword><Keyword MajorTopicYN="N">Molecular mechanisms</Keyword><Keyword MajorTopicYN="N">Rheumatic and non-rheumatic diseases</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37264223</ArticleId><ArticleId IdType="pmc">PMC10234248</ArticleId><ArticleId IdType="doi">10.1007/s11239-023-02834-6</ArticleId><ArticleId IdType="pii">10.1007/s11239-023-02834-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78:1296&#x2013;1304. doi: 10.1136/annrheumdis-2019-215213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215213</ArticleId><ArticleId IdType="pubmed">31092409</ArticleId></ArticleIdList></Reference><Reference><Citation>Sammaritano LR. Antiphospholipid syndrome. Best Pract Res Clin Rheumatol. 2020;34:101463. doi: 10.1016/j.berh.2019.101463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2019.101463</ArticleId><ArticleId IdType="pubmed">31866276</ArticleId></ArticleIdList></Reference><Reference><Citation>Gir&#xf3;n-Gonz&#xe1;lez JA, Garc&#xed;a del R&#xed;o E, Rodr&#xed;guez C, et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31:1560&#x2013;1567.</Citation><ArticleIdList><ArticleId IdType="pubmed">15290736</ArticleId></ArticleIdList></Reference><Reference><Citation>Gezer S. Antiphospholipid syndrome. Dis&#x2013;Mon DM. 2003;49:696&#x2013;741. doi: 10.1016/j.disamonth.2003.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.disamonth.2003.10.001</ArticleId><ArticleId IdType="pubmed">14679358</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Baldovino S, Schreiber K, et al. Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. Clin Mol Allergy CMA. 2016;14:6. doi: 10.1186/s12948-016-0043-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12948-016-0043-2</ArticleId><ArticleId IdType="pmc">PMC4947367</ArticleId><ArticleId IdType="pubmed">27429595</ArticleId></ArticleIdList></Reference><Reference><Citation>Barreno-Rocha SG, Guzm&#xe1;n-Silahua S, Rodr&#xed;guez-D&#xe1;vila S-D-C, et al. Antiphospholipid antibodies and lipids in hematological malignancies. Int J Mol Sci. 2022;23:4151. doi: 10.3390/ijms23084151.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23084151</ArticleId><ArticleId IdType="pmc">PMC9025841</ArticleId><ArticleId IdType="pubmed">35456969</ArticleId></ArticleIdList></Reference><Reference><Citation>Oku K, Nakamura H, Kono M, et al. Complement and thrombosis in the antiphospholipid syndrome. Autoimmun Rev. 2016;15:1001&#x2013;1004. doi: 10.1016/j.autrev.2016.07.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2016.07.020</ArticleId><ArticleId IdType="pubmed">27485012</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, Duarte-Garc&#xed;a A. Epidemiology of antiphospholipid syndrome in the general population. Curr Rheumatol Rep. 2022;23:85. doi: 10.1007/s11926-021-01038-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-01038-2</ArticleId><ArticleId IdType="pmc">PMC8727975</ArticleId><ArticleId IdType="pubmed">34985614</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Amigo M-C, Roccatello D, Khamashta M. Diagnosing antiphospholipid syndrome: &#x201c;extra-criteria&#x201d; manifestations and technical advances. Nat Rev Rheumatol. 2017;13:548&#x2013;560. doi: 10.1038/nrrheum.2017.124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2017.124</ArticleId><ArticleId IdType="pubmed">28769114</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte-Garc&#xed;a A, Pham MM, Crowson CS, et al. The epidemiology of antiphospholipid syndrome: a population-based study. Arthritis Rheumatol Hoboken NJ. 2019;71:1545&#x2013;1552. doi: 10.1002/art.40901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40901</ArticleId><ArticleId IdType="pmc">PMC6717037</ArticleId><ArticleId IdType="pubmed">30957430</ArticleId></ArticleIdList></Reference><Reference><Citation>Radin M, Sciascia S, Bazzan M, et al. Antiphospholipid syndrome is still a rare disease-estimated prevalence in the piedmont and Aosta Valley Regions of Northwest Italy: comment on the article by Duarte-Garc&#xed;a et al. Arthritis Rheumatol Hoboken NJ. 2020;72:1774&#x2013;1776. doi: 10.1002/art.41401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41401</ArticleId><ArticleId IdType="pubmed">32840055</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang JJ, Shin SH, Kim YJ, et al. Epidemiology of antiphospholipid syndrome in Korea: a nationwide population-based study. J Korean Med Sci. 2020;35:e35. doi: 10.3346/jkms.2020.35.e35.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2020.35.e35</ArticleId><ArticleId IdType="pmc">PMC7008065</ArticleId><ArticleId IdType="pubmed">32030922</ArticleId></ArticleIdList></Reference><Reference><Citation>Uthman I, Khamashta M. Ethnic and geographical variation in antiphospholipid (Hughes) syndrome. Ann Rheum Dis. 2005;64:1671&#x2013;1676. doi: 10.1136/ard.2005.038448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2005.038448</ArticleId><ArticleId IdType="pmc">PMC1755326</ArticleId><ArticleId IdType="pubmed">15919676</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreoli L, Chighizola CB, Banzato A, et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res. 2013;65:1869&#x2013;1873. doi: 10.1002/acr.22066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22066</ArticleId><ArticleId IdType="pubmed">23861221</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripodi A. Laboratory testing for lupus anticoagulants: a review of issues affecting results. Clin Chem. 2007;53:1629&#x2013;1635. doi: 10.1373/clinchem.2007.089524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2007.089524</ArticleId><ArticleId IdType="pubmed">17712001</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827&#x2013;1832. doi: 10.1182/blood-2002-02-0441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2002-02-0441</ArticleId><ArticleId IdType="pubmed">12393574</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosting JD, Derksen RH, Bobbink IW, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood. 1993;81:2618&#x2013;2625. doi: 10.1182/blood.V81.10.2618.2618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V81.10.2618.2618</ArticleId><ArticleId IdType="pubmed">8166780</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsen K, Ringdal KG, Strand K, et al. Clinical and cellular effects of hypothermia, acidosis and coagulopathy in major injury. Br J Surg. 2011;98:894&#x2013;907. doi: 10.1002/bjs.7497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.7497</ArticleId><ArticleId IdType="pubmed">21509749</ArticleId></ArticleIdList></Reference><Reference><Citation>Irish A. Renal allograft thrombosis: can thrombophilia explain the inexplicable? Nephrol Dial Transplant off Publ Eur Dial Transpl Assoc Eur Ren Assoc. 1999;14:2297&#x2013;2303. doi: 10.1093/ndt/14.10.2297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/14.10.2297</ArticleId><ArticleId IdType="pubmed">10528648</ArticleId></ArticleIdList></Reference><Reference><Citation>Green D. Pathophysiology of antiphospholipid syndrome. Thromb Haemost. 2021 doi: 10.1055/a-1701-2809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1701-2809</ArticleId><ArticleId IdType="pmc">PMC9391091</ArticleId><ArticleId IdType="pubmed">34794200</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermylen J, Carreras LO, Arnout J. Attempts to make sense of the antiphospholipid syndrome. J Thromb Haemost JTH. 2007;5:1&#x2013;4. doi: 10.1111/j.1538-7836.2006.02253.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.02253.x</ArticleId><ArticleId IdType="pubmed">17026649</ArticleId></ArticleIdList></Reference><Reference><Citation>Molhoek JE, de Groot PG, Urbanus RT. The lupus anticoagulant paradox. Semin Thromb Hemost. 2018;44:445&#x2013;452. doi: 10.1055/s-0037-1606190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1606190</ArticleId><ArticleId IdType="pubmed">28898901</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowie EJ, Thompson JH, Pascuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med. 1963;62:416&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">14061973</ArticleId></ArticleIdList></Reference><Reference><Citation>Agar C, van Os GMA, M&#xf6;rgelin M, et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010;116:1336&#x2013;1343. doi: 10.1182/blood-2009-12-260976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-12-260976</ArticleId><ArticleId IdType="pubmed">20462962</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S, Ninivaggi M, Chayoua W, de Laat B. VWF, platelets and the antiphospholipid syndrome. Int J Mol Sci. 2021;22:4200. doi: 10.3390/ijms22084200.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22084200</ArticleId><ArticleId IdType="pmc">PMC8074042</ArticleId><ArticleId IdType="pubmed">33919627</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groot PG, Meijers JCM. &#x3b2;(2)-Glycoprotein I: evolution, structure and function. J Thromb Haemost JTH. 2011;9:1275&#x2013;1284. doi: 10.1111/j.1538-7836.2011.04327.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2011.04327.x</ArticleId><ArticleId IdType="pubmed">21535391</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lummel M, Pennings MTT, Derksen RHWM, et al. The binding site in {beta}2-glycoprotein I for ApoER2&#x2019; on platelets is located in domain V. J Biol Chem. 2005;280:36729&#x2013;36736. doi: 10.1074/jbc.M504172200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M504172200</ArticleId><ArticleId IdType="pubmed">16091370</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolyada A, Barrios DA, Beglova N. Dimerized domain V of Beta2-Glycoprotein I is sufficient to upregulate procoagulant activity in PMA-treated U937 monocytes and require intact residues in two phospholipid-binding loops. Antibodies Basel Switz. 2017;6:8. doi: 10.3390/antib6020008.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib6020008</ArticleId><ArticleId IdType="pmc">PMC5523967</ArticleId><ArticleId IdType="pubmed">28748111</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver JC, Krilis SA, Giannakopoulos B. Oxidative post-translational modification of &#x3b2;eta 2-glycoprotein I in the pathophysiology of the anti-phospholipid syndrome. Free Radic Biol Med. 2018;125:98&#x2013;103. doi: 10.1016/j.freeradbiomed.2018.03.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.03.048</ArticleId><ArticleId IdType="pubmed">29604397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye C, Shen Z, Greenberg ML. Cardiolipin remodeling: a regulatory hub for modulating cardiolipin metabolism and function. J Bioenerg Biomembr. 2016;48:113&#x2013;123. doi: 10.1007/s10863-014-9591-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10863-014-9591-7</ArticleId><ArticleId IdType="pmc">PMC4449329</ArticleId><ArticleId IdType="pubmed">25432572</ArticleId></ArticleIdList></Reference><Reference><Citation>Claypool SM, Oktay Y, Boontheung P, et al. Cardiolipin defines the interactome of the major ADP/ATP carrier protein of the mitochondrial inner membrane. J Cell Biol. 2008;182:937&#x2013;950. doi: 10.1083/jcb.200801152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200801152</ArticleId><ArticleId IdType="pmc">PMC2528576</ArticleId><ArticleId IdType="pubmed">18779372</ArticleId></ArticleIdList></Reference><Reference><Citation>Marai I, Tincani A, Balestrieri G, Shoenfeld Y. Anticardiolipin and anti-beta-2-glycoprotein I antibodies. Autoimmunity. 2005;38:33&#x2013;38. doi: 10.1080/08916930400022608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930400022608</ArticleId><ArticleId IdType="pubmed">15804703</ArticleId></ArticleIdList></Reference><Reference><Citation>Aykan A, G&#xf6;kdeniz T, Kal&#xe7;&#x131;k M, et al. Role of anticardiolipin antibodies in the pathogenesis of prosthetic valve thrombosis: an observational study. Herz. 2015;40:528&#x2013;533. doi: 10.1007/s00059-013-4038-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00059-013-4038-1</ArticleId><ArticleId IdType="pubmed">24441396</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet Lond Engl. 1990;335:1544&#x2013;1547. doi: 10.1016/0140-6736(90)91374-j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(90)91374-j</ArticleId><ArticleId IdType="pubmed">1972485</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang K-K, Yang C-D, Yan W, et al. A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum. 2003;48:1622&#x2013;1630. doi: 10.1002/art.10983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10983</ArticleId><ArticleId IdType="pmc">PMC1978198</ArticleId><ArticleId IdType="pubmed">12794830</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost JTH. 2006;4:295&#x2013;306. doi: 10.1111/j.1538-7836.2006.01753.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoogen LL, van Roon JAG, Radstake TRDJ, et al. Delineating the deranged immune system in the antiphospholipid syndrome. Autoimmun Rev. 2016;15:50&#x2013;60. doi: 10.1016/j.autrev.2015.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.08.011</ArticleId><ArticleId IdType="pubmed">26318678</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam MA. Antiphospholipid antibodies and antiphospholipid syndrome in cancer: uninvited guests in troubled times. Semin Cancer Biol. 2020;64:108&#x2013;113. doi: 10.1016/j.semcancer.2019.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2019.07.019</ArticleId><ArticleId IdType="pubmed">31351197</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon KH, Wong A, Shakespeare T, Sivalingam P. High prevalence of antiphospholipid antibodies in asian cancer patients with thrombosis. Lupus. 2003;12:112&#x2013;116. doi: 10.1191/0961203303lu328oa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203303lu328oa</ArticleId><ArticleId IdType="pubmed">12630755</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassalo J, Spector N, de Meis E, et al. Antiphospholipid antibodies in critically ill patients with cancer: a prospective cohort study. J Crit Care. 2014;29:533&#x2013;538. doi: 10.1016/j.jcrc.2014.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2014.02.005</ArticleId><ArticleId IdType="pubmed">24629573</ArticleId></ArticleIdList></Reference><Reference><Citation>Bairey O, Blickstein D, Monselise Y, et al. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-hodgkin&#x2019;s lymphoma. Eur J Haematol. 2006;76:384&#x2013;391. doi: 10.1111/j.1600-0609.2005.00620.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0609.2005.00620.x</ArticleId><ArticleId IdType="pubmed">16466368</ArticleId></ArticleIdList></Reference><Reference><Citation>de Meis E, Monteiro RQ, Levy RA. Lung adenocarcinoma and antiphospholipid antibodies. Autoimmun Rev. 2009;8:529&#x2013;532. doi: 10.1016/j.autrev.2009.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2009.01.010</ArticleId><ArticleId IdType="pubmed">19185619</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Wahab N, Tayar JH, Fa&#x2019;ak F, et al. Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors. Blood Adv. 2020;4:1746&#x2013;1755. doi: 10.1182/bloodadvances.2020001557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020001557</ArticleId><ArticleId IdType="pmc">PMC7189282</ArticleId><ArticleId IdType="pubmed">32337583</ArticleId></ArticleIdList></Reference><Reference><Citation>Ediriwickrema LS, Zaheer W. Diffuse large cell lymphoma presenting as a sacral mass and lupus anticoagulant. Yale J Biol Med. 2011;84:433&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3238310</ArticleId><ArticleId IdType="pubmed">22180680</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Ying Z, Li R, et al. Clinical and immunological relevance of antiphospholipid antibodies in patients with lymphoma. Zhonghua Yi Xue Za Zhi. 2011;91:2607&#x2013;2610.</Citation><ArticleIdList><ArticleId IdType="pubmed">22321923</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuckerman E, Toubi E, Golan TD, et al. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer. 1995;72:447&#x2013;451. doi: 10.1038/bjc.1995.353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.1995.353</ArticleId><ArticleId IdType="pmc">PMC2034001</ArticleId><ArticleId IdType="pubmed">7640230</ArticleId></ArticleIdList></Reference><Reference><Citation>Miesbach W, Scharrer I, Asherson R. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clin Rheumatol. 2006;25:840&#x2013;844. doi: 10.1007/s10067-005-0181-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-005-0181-2</ArticleId><ArticleId IdType="pubmed">16435159</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaukat MN, Hughes P. Recurrent thrombosis and anticardiolipin antibodies associated with adenocarcinoma of the lung. Postgrad Med J. 1990;66:316&#x2013;318. doi: 10.1136/pgmj.66.774.316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/pgmj.66.774.316</ArticleId><ArticleId IdType="pmc">PMC2429403</ArticleId><ArticleId IdType="pubmed">2385560</ArticleId></ArticleIdList></Reference><Reference><Citation>Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis. 2003;62:388&#x2013;393. doi: 10.1136/ard.62.5.388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.62.5.388</ArticleId><ArticleId IdType="pmc">PMC1754545</ArticleId><ArticleId IdType="pubmed">12695147</ArticleId></ArticleIdList></Reference><Reference><Citation>Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum. 2002;31:256&#x2013;263. doi: 10.1053/sarh.2002.28303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/sarh.2002.28303</ArticleId><ArticleId IdType="pubmed">11836658</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME. Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus. 2018;27:572&#x2013;583. doi: 10.1177/0961203317731532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317731532</ArticleId><ArticleId IdType="pubmed">28945149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Lond Engl. 2020;395:1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin LA, Paterson RW, Moll R, et al. Antiphospholipid antibodies and neurological manifestations in acute COVID-19: a single-centre cross-sectional study. EClinicalMedicine. 2021;39:101070. doi: 10.1016/j.eclinm.2021.101070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101070</ArticleId><ArticleId IdType="pmc">PMC8358233</ArticleId><ArticleId IdType="pubmed">34401683</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha M, Samavati L. Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review. RMD Open. 2021;7:e001580. doi: 10.1136/rmdopen-2021-001580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-001580</ArticleId><ArticleId IdType="pmc">PMC8103564</ArticleId><ArticleId IdType="pubmed">33958439</ArticleId></ArticleIdList></Reference><Reference><Citation>El Hasbani G, Taher AT, Jawad A, Uthman I. COVID-19, antiphospholipid antibodies, and catastrophic antiphospholipid syndrome: a possible association? Clin Med Insights Arthritis Musculoskelet Disord. 2020;13:1179544120978667. doi: 10.1177/1179544120978667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1179544120978667</ArticleId><ArticleId IdType="pmc">PMC7720319</ArticleId><ArticleId IdType="pubmed">33328777</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubbert A, Bock E, Schwab J, et al. Anticardiolipin antibodies in HIV infection: association with cerebral perfusion defects as detected by 99mTc-HMPAO SPECT. Clin Exp Immunol. 1994;98:361&#x2013;368. doi: 10.1111/j.1365-2249.1994.tb05498.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.1994.tb05498.x</ArticleId><ArticleId IdType="pmc">PMC1534517</ArticleId><ArticleId IdType="pubmed">7994900</ArticleId></ArticleIdList></Reference><Reference><Citation>Million M, Bardin N, Bessis S, et al. Thrombosis and antiphospholipid antibody syndrome during acute Q fever: a cross-sectional study. Med (Baltim) 2017;96:e7578. doi: 10.1097/MD.0000000000007578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000007578</ArticleId><ArticleId IdType="pmc">PMC5521934</ArticleId><ArticleId IdType="pubmed">28723794</ArticleId></ArticleIdList></Reference><Reference><Citation>Million M, Walter G, Bardin N, et al. Immunoglobulin G anticardiolipin antibodies and progression to Q fever endocarditis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;57:57&#x2013;64. doi: 10.1093/cid/cit191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cit191</ArticleId><ArticleId IdType="pubmed">23532474</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C-H, Chuah S-K, Pei S-N, Liu J-W. Acute Q fever presenting as antiphospholipid syndrome, pneumonia, and acalculous cholecystitis and masquerading as Mycoplasma pneumoniae and hepatitis C viral infections. Jpn J Infect Dis. 2011;64:525&#x2013;527. doi: 10.7883/yoken.64.525.</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken.64.525</ArticleId><ArticleId IdType="pubmed">22116335</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcombe JP, Gray PEA, Palasanthiran P, Snelling TL. Q fever with transient antiphospholipid antibodies associated with cholecystitis and splenic infarction. Pediatr Infect Dis J. 2013;32:415&#x2013;416. doi: 10.1097/INF.0b013e3182843d7e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e3182843d7e</ArticleId><ArticleId IdType="pubmed">23271442</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafsson JT, Gunnarsson I, K&#xe4;llberg H, et al. Cigarette smoking, antiphospholipid antibodies and vascular events in systemic Lupus Erythematosus. Ann Rheum Dis. 2015;74:1537&#x2013;1543. doi: 10.1136/annrheumdis-2013-205159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205159</ArticleId><ArticleId IdType="pubmed">24692586</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C-Y, Chyuan I-T, Wang Y-L, et al. &#x3b2;2-Glycoprotein I-dependent anti-cardiolipin antibodies associated with periodontitis in patients with systemic Lupus Erythematosus. J Periodontol. 2015;86:995&#x2013;1004. doi: 10.1902/jop.2015.140664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1902/jop.2015.140664</ArticleId><ArticleId IdType="pubmed">25817824</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadalam PK, Rajapandian K, Ravishankar PL, et al. Evaluation of anticardiolipin antibodies in tobacco users and non-tobacco users with severe chronic periodontal disease. J Int Soc Prev Community Dent. 2016;6:256&#x2013;260. doi: 10.4103/2231-0762.183115.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2231-0762.183115</ArticleId><ArticleId IdType="pmc">PMC4916802</ArticleId><ArticleId IdType="pubmed">27382544</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassalo J, Spector N, de Meis E, et al. Antiphospholipid antibodies in critically ill patients. Rev Bras Ter Intensiva. 2014;26:176&#x2013;182. doi: 10.5935/0103-507x.20140026.</Citation><ArticleIdList><ArticleId IdType="doi">10.5935/0103-507x.20140026</ArticleId><ArticleId IdType="pmc">PMC4103945</ArticleId><ArticleId IdType="pubmed">25028953</ArticleId></ArticleIdList></Reference><Reference><Citation>Abouda A, Hajjej Z, Mansart A, et al. Anticardiolipin autoantibodies as useful biomarkers for the prediction of mortality in septic patients. J Immunol Res. 2022;2022:9775111. doi: 10.1155/2022/9775111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/9775111</ArticleId><ArticleId IdType="pmc">PMC9174012</ArticleId><ArticleId IdType="pubmed">35685432</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Puerta JA, Espinosa G, Cervera R. Antiphospholipid antibodies: from general concepts to its relation with malignancies. Antibodies Basel Switz. 2016;5:E18. doi: 10.3390/antib5030018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib5030018</ArticleId><ArticleId IdType="pmc">PMC6698865</ArticleId><ArticleId IdType="pubmed">31557999</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffatti A, Del Ross T, Ciprian M, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis. 2011;70:1083&#x2013;1086. doi: 10.1136/ard.2010.142042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.142042</ArticleId><ArticleId IdType="pubmed">21285115</ArticleId></ArticleIdList></Reference><Reference><Citation>Manukyan D, Rossmann H, Schulz A, et al. Distribution of antiphospholipid antibodies in a large population-based german cohort. Clin Chem Lab Med. 2016;54:1663&#x2013;1670. doi: 10.1515/cclm-2016-0014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2016-0014</ArticleId><ArticleId IdType="pubmed">27028736</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Sanna G, Murru V, et al. GAPSS: the global anti-phospholipid syndrome score. Rheumatol Oxf Engl. 2013;52:1397&#x2013;1403. doi: 10.1093/rheumatology/kes388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes388</ArticleId><ArticleId IdType="pubmed">23315788</ArticleId></ArticleIdList></Reference><Reference><Citation>Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64:504&#x2013;512. doi: 10.1002/art.33340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.33340</ArticleId><ArticleId IdType="pubmed">21953404</ArticleId></ArticleIdList></Reference><Reference><Citation>Radin M, Sciascia S, Erkan D, et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort. Semin Arthritis Rheum. 2019;49:464&#x2013;468. doi: 10.1016/j.semarthrit.2019.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2019.04.009</ArticleId><ArticleId IdType="pmc">PMC7402528</ArticleId><ArticleId IdType="pubmed">31153708</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Radin M, Sanna G, et al. Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis. Rheumatol Oxf Engl. 2018;57:661&#x2013;665. doi: 10.1093/rheumatology/kex466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex466</ArticleId><ArticleId IdType="pubmed">29342292</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015;14:192&#x2013;200. doi: 10.1016/j.autrev.2014.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2014.10.019</ArticleId><ArticleId IdType="pubmed">25461472</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel GJ, Andreoli L, Scanzi F, et al. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2017;76:10&#x2013;20. doi: 10.1016/j.jaut.2016.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2016.10.004</ArticleId><ArticleId IdType="pubmed">27776934</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia D, Erkan D. Diagnosis and management of the Antiphospholipid Syndrome. N Engl J Med. 2018;378:2010&#x2013;2021. doi: 10.1056/NEJMra1705454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1705454</ArticleId><ArticleId IdType="pubmed">29791828</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervera R, Piette J-C, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum. 2002;46:1019&#x2013;1027. doi: 10.1002/art.10187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10187</ArticleId><ArticleId IdType="pubmed">11953980</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Egurbide M-V, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med. 2004;164:77&#x2013;82. doi: 10.1001/archinte.164.1.77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.164.1.77</ArticleId><ArticleId IdType="pubmed">14718326</ArticleId></ArticleIdList></Reference><Reference><Citation>El Hasbani G, Viola M, Sciascia S, et al. Antiphospholipid antibodies in inflammatory and autoimmune rheumatic and musculoskeletal diseases beyond lupus: a systematic review of the available evidence. Rheumatol Ther. 2021;8:81&#x2013;94. doi: 10.1007/s40744-020-00273-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40744-020-00273-w</ArticleId><ArticleId IdType="pmc">PMC7991011</ArticleId><ArticleId IdType="pubmed">33420626</ArticleId></ArticleIdList></Reference><Reference><Citation>Merashli M, Alves J, Ames PRJ. Clinical relevance of antiphospholipid antibodies in systemic sclerosis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2017;46:615&#x2013;624. doi: 10.1016/j.semarthrit.2016.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2016.10.004</ArticleId><ArticleId IdType="pubmed">27838012</ArticleId></ArticleIdList></Reference><Reference><Citation>Marie I, Jouen F, Hellot M-F, Levesque H. Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol. 2008;158:141&#x2013;144. doi: 10.1111/j.1365-2133.2007.08309.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2007.08309.x</ArticleId><ArticleId IdType="pubmed">18028496</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasoto SG, Chakkour HP, Natalino RR, et al. Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sj&#xf6;gren&#x2019;s syndrome. Clin Rheumatol. 2012;31:1331&#x2013;1338. doi: 10.1007/s10067-012-2019-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-012-2019-z</ArticleId><ArticleId IdType="pubmed">22692396</ArticleId></ArticleIdList></Reference><Reference><Citation>Olech E, Merrill JT. The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis. Curr Rheumatol Rep. 2006;8:100&#x2013;108. doi: 10.1007/s11926-006-0049-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-006-0049-8</ArticleId><ArticleId IdType="pubmed">16569368</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipowicz-Sosnowska A, Rupi&#x144;ski R, Walewska E. The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis. Pol Arch Med Wewn. 2007;117:33&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18778017</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakane T, Takeno M, Suzuki N, Inaba G. Beh&#xe7;et&#x2019;s disease. N Engl J Med. 1999;341:1284&#x2013;1291. doi: 10.1056/NEJM199910213411707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199910213411707</ArticleId><ArticleId IdType="pubmed">10528040</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Houwen TB, van Hagen PM, van Laar J. Immunopathogenesis of Beh&#xe7;et&#x2019;s disease and treatment modalities. Semin Arthritis Rheum. 2022;52:151956. doi: 10.1016/j.semarthrit.2022.151956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2022.151956</ArticleId><ArticleId IdType="pubmed">35038644</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam MA, Alam SS, Kundu S, et al. Prevalence of antiphospholipid antibodies in Beh&#xe7;et&#x2019;s disease: a systematic review and meta-analysis. PLoS ONE. 2020;15:e0227836. doi: 10.1371/journal.pone.0227836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0227836</ArticleId><ArticleId IdType="pmc">PMC6957187</ArticleId><ArticleId IdType="pubmed">31929597</ArticleId></ArticleIdList></Reference><Reference><Citation>Simchen MJ, Dulitzki M, Rofe G, et al. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand. 2011;90:1428&#x2013;1433. doi: 10.1111/j.1600-0412.2011.01236.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0412.2011.01236.x</ArticleId><ArticleId IdType="pubmed">21729009</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012;64:2311&#x2013;2318. doi: 10.1002/art.34402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34402</ArticleId><ArticleId IdType="pmc">PMC3357451</ArticleId><ArticleId IdType="pubmed">22275304</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing Y, Wen L, Zhang J, et al. Angiogenic markers could predict adverse pregnancy outcomes. Clin Exp Med. 2021 doi: 10.1007/s10238-021-00764-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-021-00764-2</ArticleId><ArticleId IdType="pubmed">34741679</ArticleId></ArticleIdList></Reference><Reference><Citation>Chighizola CB, de Jesus GR, Branch DW. The hidden world of anti-phospholipid antibodies and female infertility: a literature appraisal. Autoimmun Rev. 2016;15:493&#x2013;500. doi: 10.1016/j.autrev.2016.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2016.01.018</ArticleId><ArticleId IdType="pubmed">26827907</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues V, de O, Soligo A, de GES, Pannain GD. Antiphospholipid antibody syndrome and infertility. Rev Bras Ginecol E Obstet Rev Fed Bras Soc Ginecol E Obstet. 2019;41:621&#x2013;627. doi: 10.1055/s-0039-1697982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-1697982</ArticleId><ArticleId IdType="pubmed">31658490</ArticleId></ArticleIdList></Reference><Reference><Citation>Kov&#xe1;cs M, Hartwig M, Aleksza M, et al. Antiphospholipid antibodies in relation to sterility/infertility. Hum Immunol. 2012;73:726&#x2013;731. doi: 10.1016/j.humimm.2012.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2012.04.003</ArticleId><ArticleId IdType="pubmed">22548718</ArticleId></ArticleIdList></Reference><Reference><Citation>Chighizola CB, Raimondo MG, Meroni PL. Does APS impact Women&#x2019;s fertility? Curr Rheumatol Rep. 2017;19:33. doi: 10.1007/s11926-017-0663-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-017-0663-7</ArticleId><ArticleId IdType="pubmed">28470478</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamakami LYS, Serafini PC, de Araujo DB, et al. Ovarian reserve in women with primary antiphospholipid syndrome. Lupus. 2014;23:862&#x2013;867. doi: 10.1177/0961203314529468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314529468</ArticleId><ArticleId IdType="pubmed">24668362</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao R, Zeng R, Qing P, et al. Antiphospholipid antibodies and pregnancy outcome of assisted reproductive treatment: a systematic review and meta-analysis. Am J Reprod Immunol N Y N 1989. 2021;86:e13470. doi: 10.1111/aji.13470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aji.13470</ArticleId><ArticleId IdType="pubmed">34018271</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarne-Borr&#xe0;s M, Mir&#xf3;-Mur F, Anunciaci&#xf3;n-Llunell A, Alijotas-Reig J. Antiphospholipid antibodies in women with recurrent embryo implantation failure: a systematic review and meta-analysis. Autoimmun Rev. 2022;21:103101. doi: 10.1016/j.autrev.2022.103101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2022.103101</ArticleId><ArticleId IdType="pubmed">35452853</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetti T, Cohen M, Gris J-C, de Moerloose P. Diagnosis and management of obstetrical antiphospholipid syndrome: where do we stand? Pol Arch Med Wewn. 2013;123:713&#x2013;720. doi: 10.20452/pamw.2025.</Citation><ArticleIdList><ArticleId IdType="doi">10.20452/pamw.2025</ArticleId><ArticleId IdType="pubmed">24382555</ArticleId></ArticleIdList></Reference><Reference><Citation>Latino JO, Udry S, Wingeyer SP, et al. What is the best time to assess the antiphospholipid antibodies (aPL) profile to better predict the obstetric outcome in antiphospholipid syndrome (APS) patients? Immunol Res. 2018;66:577&#x2013;583. doi: 10.1007/s12026-018-9024-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-018-9024-5</ArticleId><ArticleId IdType="pubmed">30159862</ArticleId></ArticleIdList></Reference><Reference><Citation>Gris J-C, Bouvier S, Nouvellon E, et al. Antiphospholid antibodies and the risk of pregnancy complications. Thromb Res. 2017;151(Suppl 1):S34&#x2013;S37. doi: 10.1016/S0049-3848(17)30064-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0049-3848(17)30064-6</ArticleId><ArticleId IdType="pubmed">28262231</ArticleId></ArticleIdList></Reference><Reference><Citation>Qushmaq NA, Al-Emadi SA. Review on effectiveness of primary Prophylaxis in aPLs with and without risk factors for thrombosis: efficacy and safety. ISRN Rheumatol. 2014;2014:348726. doi: 10.1155/2014/348726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/348726</ArticleId><ArticleId IdType="pmc">PMC4040209</ArticleId><ArticleId IdType="pubmed">24944829</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen H, Cuadrado MJ, Erkan D, et al. 16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Lupus. 2020;29:1571&#x2013;1593. doi: 10.1177/0961203320950461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320950461</ArticleId><ArticleId IdType="pmc">PMC7658424</ArticleId><ArticleId IdType="pubmed">33100166</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayar Z, Moll R, Isenberg D, Cohen H. Thrombotic antiphospholipid syndrome: a practical guide to diagnosis and management. Thromb Res. 2021;198:213&#x2013;221. doi: 10.1016/j.thromres.2020.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.10.010</ArticleId><ArticleId IdType="pmc">PMC7560059</ArticleId><ArticleId IdType="pubmed">33485122</ArticleId></ArticleIdList></Reference><Reference><Citation>Costedoat-Chalumeau N, Guettrot-Imbert G, Leguern V, et al. Pregnancy and antiphospholipid syndrome. Rev Med Interne. 2012;33:209&#x2013;216. doi: 10.1016/j.revmed.2012.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.revmed.2012.01.003</ArticleId><ArticleId IdType="pubmed">22341691</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye S-L, Gu X-K, Tao L-Y, et al. Efficacy of different treatment regimens for antiphospholipid syndrome-related recurrent spontaneous abortion. Chin Med J (Engl) 2017;130:1395&#x2013;1399. doi: 10.4103/0366-6999.207471.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0366-6999.207471</ArticleId><ArticleId IdType="pmc">PMC5463467</ArticleId><ArticleId IdType="pubmed">28584200</ArticleId></ArticleIdList></Reference><Reference><Citation>Mekinian A, Lazzaroni MG, Kuzenko A, et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a european multicenter retrospective study. Autoimmun Rev. 2015;14:498&#x2013;502. doi: 10.1016/j.autrev.2015.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.01.012</ArticleId><ArticleId IdType="pubmed">25617818</ArticleId></ArticleIdList></Reference><Reference><Citation>Devreese KMJ, Ortel TL, Pengo V, et al. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost JTH. 2018;16:809&#x2013;813. doi: 10.1111/jth.13976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13976</ArticleId><ArticleId IdType="pubmed">29532986</ArticleId></ArticleIdList></Reference><Reference><Citation>Arachchillage DRJ, Gomez K, Alikhan R, et al. Addendum to british society for haematology guidelines on investigation and management of antiphospholipid syndrome, 2012 (br. J. Haematol. 2012; 157: 47&#x2013;58): use of direct acting oral anticoagulants. Br J Haematol. 2020;189:212&#x2013;215. doi: 10.1111/bjh.16308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16308</ArticleId><ArticleId IdType="pubmed">31943138</ArticleId></ArticleIdList></Reference><Reference><Citation>Devreese KMJ, de Groot PG, de Laat B, et al. Guidance from the scientific and standardization committee for lupus anticoagulant/antiphospholipid antibodies of the international society on thrombosis and haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost JTH. 2020;18:2828&#x2013;2839. doi: 10.1111/jth.15047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15047</ArticleId><ArticleId IdType="pubmed">33462974</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearon C, Parpia S, Spencer FA, et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 2018;131:2151&#x2013;2160. doi: 10.1182/blood-2017-09-805689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2017-09-805689</ArticleId><ArticleId IdType="pmc">PMC6536697</ArticleId><ArticleId IdType="pubmed">29490924</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>